High-throughput small-molecule assays play essential roles in biomedical diagnosis, drug discovery, environmental analysis, and physiological function research. Nanoplasmonics holds a great potential for the label-free detection of small molecules at extremely low concentrations. Here, we report the development of nanoplasmonic paper (NP-paper) for the rapid separation and ultrasensitive detection of mixed small molecules. NP-paper employs nanogap-rich silver nanoislands on cellulose fibers, which were simply fabricated at the wafer level by using low-temperature solid-state dewetting of a thin silver film. The nanoplasmonic detection allows for the scalable quantification and identification of small molecules over broad concentration ranges. Moreover, the combination of chromatographic separation and nanoplasmonic detection allows both the highly sensitive fluorescence detection of mixed small molecules at the attogram level and the label-free detection at the sub-nanogram level based on surface-enhanced Raman scattering. This novel material provides a new diagnostic platform for the high-throughput, low-cost, and label-free screening of mixed small molecules as an alternative to conventional paper chromatography. A nanoplasmonic paper (NP-paper) consisting of silver nanoislands on cellulose fibers has been used for ultrasensitive detection of small molecules. The detection and quantification of small molecules is important for many applications including clinical diagnosis, drug discovery, and environmental analysis, but conventional analysis methods suffer from low throughputs and are thus expensive. Now, a research team at Korea Advanced Institute of Science and Technology led by Ki-Hun Jeong has fabricated an inexpensive NP-paper that is capable of performing rapid chromatographic separation and ultrasensitive detection of diverse small molecules. Mixed small molecules can be detected at an attogram level by plasmon-enhanced fluorescence spectroscopy and at a sub-nanogram level by surface-enhanced Raman scattering, which has the advantage of being label free. Thus, this platform offers high-throughput, low-cost, and label-free screening and detection of small-molecule mixtures.
No takes yet. Share an insight, caveat, or question.
Jung et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: